Wells Fargo
BIB icon

Wells Fargo’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Wells Fargo’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65 Hold
1
– – ﹤0.01% 6692
2026
Q1 		$89 Sell
1
-1
-50% -$83 ﹤0.01% 6517
2025
Q4 		$145 Buy
2
+1
+100% +$74 ﹤0.01% 6406
2025
Q3 		$67 Buy
+1
New +$54 ﹤0.01% 6441
2025
Q2 		– Sell
-1
Closed -$44 – 6802
2025
Q1 		$29 Sell
1
-1
-50% -$54 ﹤0.01% 6564
2024
Q4 		$77 Buy
2
+1
+100% +$59 ﹤0.01% 6446
2024
Q3 		$35 Hold
1
– – ﹤0.01% 6416
2024
Q2 		$41 Hold
1
– – ﹤0.01% 6350
2024
Q1 		$81 Hold
1
– – ﹤0.01% 6710
2023
Q4 		$43 Sell
1
-1,849
-100% -$86.7K ﹤0.01% 6961
2023
Q3 		$88.7K Sell
1,850
-1
-0.1% -$51 ﹤0.01% 4845
2023
Q2 		$96.3K Buy
1,851
+1
+0.1% +$55 ﹤0.01% 5064
2023
Q1 		$100K Buy
+1,850
New +$104K ﹤0.01% 4797

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Wells Fargo's BIB Position: Q2 2026 in Review

Wells Fargo held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q2 2026 at 1 share worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #6692.

Wells Fargo first reported a position in BIB in Q1 2023 and has held it in 13 quarters since. The position peaked at $100K in Q1 2023. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Wells Fargo held 1 share of ProShares Ultra NASDAQ Biotechnology worth $65 as of Q2 2026.
  • Wells Fargo left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q2 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6692 holding.
  • Wells Fargo first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2023 and has held it in 13 quarters since.
  • Wells Fargo's ProShares Ultra NASDAQ Biotechnology position peaked at $100K in Q1 2023.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.